Lynne V Abruzzo

List of Publications by Year
in descending order

27	1,170	933447 10	677142 22
papers	citations	h-index	g-index

28	28	28	1845
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Electronic Health Records and Genomics. Journal of Molecular Diagnostics, 2022, 24, 1-17.	2.8	8
2	Four-year follow-up from a phase 2 study of obinutuzumab, ibrutinib, and venetoclax in CLL.. Journal of Clinical Oncology, 2022, 40, 7540-7540.	1.6	2
3	Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia. Journal of Hematology and Oncology, 2021, 14, 17.	17.0	31
4	Pattern recognition in lymphoid malignancies using CytoGPS and Mercator. BMC Bioinformatics, 2021, 22, 100.	2.6	2
5	Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients. Leukemia, 2021, 35, 3287-3290.	7.2	0
6	Genomic analysis of cellular hierarchy in acute myeloid leukemia using ultrasensitive LC-FACSeq. Leukemia, 2021, 35, 3406-3420.	7.2	3
7	RCytoGPS: an R package for reading and visualizing cytogenetics data. Bioinformatics, 2021, 37, 4589-4590.	4.1	3
8	Normal FISH CLL Represents a Heterogeneous Subgroup Where Prognosis Can be Refined with IGHV Mutational Status. Blood, 2021, 138, 1563-1563.	1.4	0
9	CytoGPS: A large-scale karyotype analysis of CML data. Cancer Genetics, 2020, 248-249, 34-38.	0.4	2
10	Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-NaÃ¯ve and Relapsed or Refractory Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2020, 38, 3626-3637.	1.6	71
11	Unsupervised machine learning and prognostic factors of survival in chronic lymphocytic leukemia. Journal of the American Medical Informatics Association: JAMIA, 2020, 27, 1019-1027.	4.4	18
12	Increasing Karyotypic Complexity Predicts Outcomes in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. Blood, 2020, 136, 2-3.	1.4	1
13	Three-Year Follow-up from a Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia. Blood, 2020, 136, 9-10.	1.4	12
14	Final Results of a Phase II Study of Fc Engineered, CD19 Antibody Tafasitamab in Combination with Lenalidomide or Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL). Blood, 2020, 136, 22-23.	1.4	1
15	CytoGPS: a web-enabled karyotype analysis tool for cytogenetics. Bioinformatics, 2019, 35, 5365-5366.	4.1	8
16	Developmental subtypes assessed by DNA methylation-iPLEX forecast the natural history of chronic lymphocytic leukemia. Blood, 2019, 134, 688-698.	1.4	26
17	Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study. Lancet Oncology, The, 2019, 20, 1576-1586.	10.7	26
18	Inferring clonal heterogeneity in cancer using SNP arrays and whole genome sequencing. Bioinformatics, 2019, 35, 2924-2931.	4.1	3

#	Article	IF	Citations
19	Thirty biologically interpretable clusters of transcription factors distinguish cancer type. BMC Genomics, 2018, 19, 738.	2.8	6
20	Trisomy 12 chronic lymphocytic leukemia expresses a unique set of activated and targetable pathways. Haematologica, 2018, 103, 2069-2078.	3.5	25
21	Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers. Clinical Cancer Research, 2017, 23, 2891-2904.	7.0	122
22	Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nature Communications, 2016, 7, 11589.	12.8	285
23	the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL. Blood, 2016, 128, 55-55.	1.4	8
24	Near-Tetraploidy Is Strongly Associated with Development of Richter's Transformation in Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib. Blood, 2016, 128, 3198-3198.	1.4	0
25	Aberrant Methylation and Decreased Expression of NRIP1 in IGHV-Unmutated CLL. Blood, 2016, 128, 1527-1527.	1.4	0
26	Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. JAMA Oncology, 2015, 1, 80.	7.1	498
27	Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation. Cancer Genetics, 2015, 208, 571-574.	0.4	9